Literature DB >> 7806781

Syndromic classification in the management of childhood epilepsy.

J Aicardi1.   

Abstract

Epilepsy syndromes, defined as clusters of symptoms or signs occurring consistently together, form the basis of the currently accepted classification of the epilepsies. The concept of epilepsy syndrome is practical for the diagnosis, prognosis, orientation of treatment, and selection of appropriate investigations, but it is of variable specificity and usually does not give information on causes and mechanisms of an epilepsy. Some syndromes, such as childhood absences, partial epilepsy with centrotemporal spikes, or juvenile myoclonic epilepsy, are precisely characterized while other syndromes such as grand mal on awakening or the multiple syndromes with myoclonic seizures are poorly delineated. The usefulness of the concept is limited to well-defined and generally accepted syndromes and many cases of epilepsy do not fit easily in recognizable syndromes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7806781

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  4 in total

1.  Networks underlying paroxysmal fast activity and slow spike and wave in Lennox-Gastaut syndrome.

Authors:  Neelan Pillay; John S Archer; Radwa A B Badawy; Danny F Flanagan; Samuel F Berkovic; Graeme Jackson
Journal:  Neurology       Date:  2013-07-17       Impact factor: 9.910

Review 2.  Advances in neurology.

Authors:  C R Kennedy
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

3.  Polymorphism of ABCB1/MDR1 C3435T in children and adolescents with partial epilepsy is due to different criteria for drug resistance - preliminary results.

Authors:  Ewa Emich-Widera; Wirginia Likus; Beata Kazek; Aleksander L Sieroń; Ksymena Urbanek
Journal:  Med Sci Monit       Date:  2014-09-16

Review 4.  Classifying epilepsy pragmatically: Past, present, and future.

Authors:  Nathan A Shlobin; Gagandeep Singh; Charles R Newton; Josemir W Sander
Journal:  J Neurol Sci       Date:  2021-05-29       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.